Please assess the completion status of the following clinical trial:

Trial Title: Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subject is able to understand and comply with protocol requirements and instructions and is likely to complete the study as planned, as well as provided a written consent.~* A subject age between ≥20 and \<75 years at time of informed consent.~* A subject who applies to one of the following:~Female subject with non-childbearing potential \[i.e., physiologically incapable of becoming pregnant, who: has had a hysterectomy, or had a bilateral oophorectomy (ovariectomy), or had a bilateral tubal ligation, or is post-menopausal for greater than one year\].~Female subject with childbearing potential, has a negative urine or serum pregnancy test at screening and within the 24-hour period prior to the first dose of SB-497115-GR, and completely abstains from intercourse or agree to use two of the following acceptable methods of contraception for 14 days before exposure to SB-497115-GR, throughout the clinical trial, and for 24 weeks after completion or premature discontinuation from the study.~Intrauterine device or intrauterine system that meets the effectiveness criteria as stated in the product label.~Male partner sterilization prior to the female subject's entry into the study, and this male is the sole partner for that subject.~Double-barrier contraception (condom with spermicidal jelly, or diaphragm with spermicide).~Male subject with childbearing potential partner completely abstains from intercourse or agree to use condom and diaphragm with spermicide.~* Subjects who were diagnosed as hepatitis C or compensated liver cirrhosis (Child-Pugh class A) without hepatic encephalopathy, or ascites. If there is a clear cirrhosis, treatment should be given with care as there is a potential of progressing to liver failure.~* Subjects who, in the opinion of the investigator, are appropriate candidates for Peg-IFN and RBV combination therapy for 48 weeks.~* HCV positive by TaqMan test at screening.~* Subject who fulfil all the organ functions below.~Items Values Platelet \<80,000 /μL Haemoglobin ≥12.0 g/dL\* Absolute neutrophil count (ANC) ≥1500 /μL\* Creatinine clearance \>50 mL/minute Total bilirubin \<2.0 mg/dL Albumin \>3.0 g/dL Prothrombin time \>60%~\*If the investigators consider the values are sufficient to give Peg-IFN/RBV, then a subject can be enrolled upon consulting the Medical Monitor.~Exclusion Criteria:~* Subject who relapsed or did not respond after 48 weeks of Peg-IFN/RBV therapy had been given with sufficient dose previously.~* Subject with history of IFN (including Peg-IFN) therapy or Peg-IFN/RBV therapy, but could not been treated with optimal Peg-IFN/RBV therapy due to the reasons other than thrombocytopenia.~* Subject who received IFN therapy (including Peg-IFN), antiviral therapy (excluding oseltamivir phosphate, etc.), immuno-modulatory treatment, radiotherapy or phlebotomy within 3 months (90 days) prior to the first dose of SB-497115-GR.~* Treatment with an investigational drug within 30 days prior to the first dose of SB-497115-GR or 5 half-lives of that investigational drug (whichever is longer).~* Subject with decompensated liver disease.~* Chronic liver disease other than chronic hepatitis C (e.g., autoimmune hepatitis, alcohol-induced hepatitis, drug-induced hepatitis, etc.).~* Subject with idiopathic thrombocytopenic purpura or active autoimmune disease.~* Subject who have had a malignancy diagnosed and/or treated within the past 5 years.~* Subjects who require endoscopic treatment for varices or documented history of clinically significant bleeding from oesophageal or gastric varices.~* Any disease condition associated with active bleeding or requiring anticoagulation with heparin or warfarin.~* Subject with serious cardiac, cerebrovascular, chronic pulmonary disease or interstitial lung disease, or documented history of any of these diseases.~* Pre-existing cardiac disease (congestive heart failure in New York Heart Association Grade III/IV), or arrhythmias known to involve the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a QTcF \>450 msec or if with bundle brunch block, QTcF \>480 msec.~* Subject with depression, psychiatric disorder requiring treatment or suicidal ideation or suicide attempt history, or history of these.~* Subject with uncontrolled hypertension (≥160 mmHg systolic or ≥100 mmHg diastolic).~* Subject with diabetes mellitus that can not be controlled by treatment.~* Thyroid dysfunction not adequately controlled.~* Subjects with haemoglobinopathies.~* History or current condition of seizure disorder.~* Subject who was positive for Human Immunodeficiency Virus (HIV) antibody or Hepatitis B Virus (HBV) antigen.~* Subject with arterial or venous thrombosis history or evidence of portal vein thrombosis on abdominal imaging (e.g., by computerized tomography or magnetic resonance imaging) within 3 months.~* History of alcohol/drug abuse or dependence.~* History of platelet clumping that prevents reliable measurement of platelet counts.~* Subjects planning to have cataract surgery.~* History of major organ transplantation.~* Known hypersensitivity to SB-497115-GR ingredients, IFN (including Peg-IFN), nucleoside analogues or biological agents (i.e., vaccines).~* Pregnant or nursing women or a male subject with pregnant partner.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- SB-497115-GR (Type: EXPERIMENTAL): investigational product for thrombocytopenia

Based on this trial design, predict the completion outcome and termination type (if applicable).